interferon induced transmembrane protein 3Genealiases: 1-8U · DSPA2b · IP15
Q-omics provides the consensus-scored IFITM3 profile across patient tissues and cancer cell-line models. IFITM3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IFITM3 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, IFITM3 protein abundance shows 18,515 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, COAD, and PDAC as cancer lineages where IFITM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFITM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFITM3 survival associations across molecular data types. IFITM3 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFITM3 RNA expression–survival associations across cancer types. High IFITM3 expression shows unfavorable associations in LGG, UVM, ACC and KIRP, but favorable associations in SKCM and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IFITM3 RNA expression.
This table summarizes IFITM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IFITM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFITM3 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, HNSC, KIRC and READ. The COAD box plot shows higher IFITM3 RNA expression in tumor versus normal tissue (log2 FC = +2.340, t-test p < 0.001).
This table shows molecular features associated with IFITM3 in patient tissues and cancer cell lines. In patient samples, IFITM3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, IFITM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LIVER.
